# GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

> **NCT05003895** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 38 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** CAR-T cell
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05003895
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05003895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05003895, "GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05003895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*